Compare ALK & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALK | TGTX |
|---|---|---|
| Founded | 1932 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.5B |
| IPO Year | N/A | 1995 |
| Metric | ALK | TGTX |
|---|---|---|
| Price | $51.34 | $30.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $69.25 | $54.75 |
| AVG Volume (30 Days) | ★ 3.4M | 1.4M |
| Earning Date | 01-21-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.23 | ★ 2.78 |
| Revenue | ★ $14,141,000,000.00 | $531,898,000.00 |
| Revenue This Year | $22.83 | $87.88 |
| Revenue Next Year | $7.28 | $48.75 |
| P/E Ratio | $41.93 | ★ $11.19 |
| Revenue Growth | 31.50 | ★ 100.88 |
| 52 Week Low | $37.63 | $25.28 |
| 52 Week High | $78.08 | $46.48 |
| Indicator | ALK | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.54 | 46.61 |
| Support Level | $50.91 | $29.79 |
| Resistance Level | $53.72 | $31.37 |
| Average True Range (ATR) | 1.81 | 1.03 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 62.69 | 49.61 |
Alaska Air Group Inc operates two airlines, Alaska and Horizon in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico, and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements (CPA). The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary and Mileage Plan passenger revenue.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.